Trials / Completed
CompletedNCT02193139
Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of An Anticholinergic Agent for the Treatment of Primary Axillary Hyperhidrosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 195 (actual)
- Sponsor
- Watson Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 2 study is designed to evaluate multiple doses of an anticholinergic-containing medication and identify the dose or doses that may effectively reduce axillary sweating in hyperhidrotic subjects. The anticholinergic agent being studied is designated WL8713.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | WL8713, 6 mg | |
| DRUG | WL8713, 12 mg | |
| DRUG | WL8713, 18 mg | |
| DRUG | WL8713, 24 mg | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2014-07-17
- Last updated
- 2015-08-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02193139. Inclusion in this directory is not an endorsement.